OrganiGram (OGI)
(Delayed Data from NSDQ)
$1.93 USD
-0.02 (-1.03%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.92 -0.01 (-0.52%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum D VGM
OrganiGram (OGI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.07 | $3.89 | $2.28 | 57.44% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for OrganiGram comes to $3.07. The forecasts range from a low of $2.28 to a high of $3.89. The average price target represents an increase of 57.44% from the last closing price of $1.95.
Analyst Price Targets (5 )
Broker Rating
OrganiGram currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.83 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 16.67% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 16.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 3 | 3 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 2 | 2 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.83 | 1.83 | 2.17 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/15/2024 | Alliance Global Partners | Aaron Grey | Hold | Strong Buy |
4/3/2024 | ATB Capital Markets | Frederico Gomes | Strong Buy | Strong Buy |
2/16/2024 | Haywood Securities | Neal Gilmer | Hold | Strong Buy |
12/20/2023 | Canaccord Genuity | Matt Bottomley | Not Available | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 6 |
Average Target Price | $3.07 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 152 of 252 |
Current Quarter EPS Est: | -0.06 |